Novo Nordisk shares rise 7% after the latest drug from the maker of weight loss drug Ozempic shows promise - ORSOLTECH

The new treatment targets the gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger. Read more